Lichao Xing

Title: Lichao Xing: Innovator in Cancer Treatment

Introduction

Lichao Xing is a notable inventor based in Jinan, China. He has made significant contributions to the field of medicine, particularly in the treatment of non-small cell lung carcinoma. His innovative approach has led to the development of a unique strain that shows promise in cancer therapy.

Latest Patents

Lichao Xing holds a patent for the "Application of Derivatives of Clostridium Ghonii," specifically focusing on the derivatives of MW-DCG-HNCv-18. This invention details the preparation of medicines aimed at treating non-small cell lung carcinoma. The patent reveals that the MW-DCG-HNCv-18 strain exhibits a specific inhibitory effect on non-small cell lung carcinoma, which is significantly superior to that of other known similar strains. Furthermore, it has been discovered that the MW-DCG-HNCv-18 strain, when combined with Docetaxel, shows a more pronounced inhibition effect on the cancer.

Career Highlights

Throughout his career, Lichao Xing has worked with prominent companies in the biotechnology and pharmaceutical sectors. He has been associated with Shandong Xinchuang Biotechnology Co., Ltd. and Shihuida Pharmaceutical Group (Jilin) Co., Ltd. His work in these organizations has contributed to advancements in medical treatments and research.

Collaborations

Lichao Xing has collaborated with several professionals in his field, including Laitian Xing and Yong Wang. These partnerships have facilitated the exchange of ideas and innovations, further enhancing his contributions to cancer treatment.

Conclusion

Lichao Xing's innovative work in the application of derivatives for cancer treatment showcases his dedication to advancing medical science. His patent and collaborations highlight the potential for new therapies in combating non-small cell lung carcinoma.